Abstract
Introduction
In psoriasis, a common immune-mediated disease affecting 2-3% of the population worldwide [1, 2] , there is an increased prevalence of extracutaneous diseases including obesity, the metabolic syndrome, and cardiovascular disease. An increase in mortality rates, especially in severe psoriasis, has been identified [3] [4] [5] [6] , and several studies have suggested that psoriasis is an independent DOI: 10.1159/000491819 risk factor for cardiovascular events [5, [7] [8] [9] . In fact, psoriasis patients have been shown to be in a so called prothrombotic state, implying a disturbance in homeostasis between coagulation and fibrinolysis along with an increased platelet activity, predisposing to cardiovascular thrombotic events [10, 11] .
In previous studies, we have explored various markers in plasma and serum to characterize the ongoing systemic inflammation in psoriasis patients compared to controls. We have identified several circulating cytokines, chemokines, and factors associated with cardiovascular disease that were elevated systemically in psoriasis but were unresponsive to narrowband (NB)-ultraviolet (UV) B treatment [12, 13] .
We here identify additional biomarkers, which demonstrate a clear response to 10-12 weeks of NB-UVB treatment. The baseline levels of endocan-1, CXCL16, and soluble vascular endothelial growth factor receptor 1 (VEGFR1) were significantly reduced in psoriasis patients compared to controls. Upon NB-UVB treatment, endocan-1 and CXCL16 were normalized to control levels, while sVEGFR1 showed a further decrease. We also observed that fatty acid-binding protein (FABP) 3, FABP4, and soluble type I interleukin-1 receptor (sIL-1R1), which showed no significant differences between patients and controls at baseline, were significantly reduced upon NB-UVB treatment. 
Results

Clinical Parameters of Metabolic and Vascular Disease
The psoriasis patients displayed a significantly higher body mass index (BMI) (median BMI 28.8, range 20.0-37.5) than the controls (median BMI 25.0, range 20.8-30.1) (p = 0.01). The waist-to-hip ratio (WHR) was also significantly higher among the patients (median 0.98, range 0.74-1.26) than among the controls (median 0.90, range 0.68-1.06) (p = 0.02). Measurements of total cholesterol, LDL and HDL cholesterol, triglycerides, and apolipoproteins A1 and B together with blood glucose and HbA 1c did not differ between the psoriasis patients and the controls.
Levels of Potential Biomarkers in Psoriasis
Measurements of a wide array of biomarkers of cardiovascular risk and systemic inflammation were performed in 35-37 age-and gender-matched patients and controls. The median baseline Psoriasis Area Severity Index (PASI) score for the psoriasis patients was 7.5 (range 1.2-25.3). The level of endocan-1 was found to be markedly reduced in the psoriasis patients compared to the controls (p = 0.009; Fig. 2a ). Interestingly, endocan-1 also showed a negative correlation to the PASI (r = -0.3; p = 0.045), with increasing severity correlating with lower endocan-1 levels. Furthermore, the level of the chemokine CXCL16 was decreased in the psoriasis patients compared to the controls (p = 0.02; Fig. 2b ). When matched for WHR and BMI, these differences receded. We found no statistically significant difference in baseline levels of thrombomodulin, pecam-1, pentraxin (PTX) 3, oncostatin M, FABP3, FABP4, and CXCL6 between the psoriasis patients and the control subjects.
Among the soluble receptors, we detected reduced levels of sVEGFR1 in the patients (p = 0.05; Fig. 2c) . No significant differences in soluble interleukin receptors, soluble tumor necrosis factor receptors, or VEGFR2 and 3 could be detected between the patients and the controls.
Influence of NB-UVB Therapy on Biomarker Levels
We compared the levels of the biomarkers before and after 10-12 weeks of NB-UVB therapy in the psoriasis patients. The levels of endocan-1 and CXCL16, which were both reduced at baseline in the psoriasis patients, were normalized to control levels after NB-UVB therapy (p = 0.008 and p = 0.002, respectively; Fig. 3a, b) . In the same patients, NB-UVB therapy further reduced the already decreased levels of sVEGFR1 (p = 0.04; Fig. 3c) .
Furthermore, FABP3, FABP4, and sIL-1R1, which had similar levels in the patients and the controls at baseline, demonstrated a significant decrease in the patients upon NB-UVB treatment (p = 0.03, p = 0.04, and p = 0.005, respectively; Fig. 3d-f ).
There was a significant reduction in PASI scores after NB-UVB treatment, the median PASI score before treatment being 8.3 (range 2.2-17.2) and after treatment 1.8 (range 0.0-5.6) (p < 0.0001).
Discussion
It has become increasingly evident that many immune-mediated diseases share an increased risk for cardiovascular disease. Inflammatory mechanisms affect homeostasis of the vascular endothelium, leading to endothelial dysfunction locally in the targeted tissue and often also systemically. Finding biomarkers that not only reflect the psoriasis disease state but are also indicative of associated comorbidities would be highly valuable.
In this study, we analyzed the levels of a multitude of potential biomarkers that are also markers of cardiovascular risk in order to investigate their suitability as biomarkers and whether they can be used for quantitation of the treatment response to UVB. In doing so, we identified three mediators whose expression was reduced in psoriasis: endocan-1, CXCL16, and sVEGFR1.
Interestingly, while the biomarkers we had previously explored in psoriasis tended to remain unaffected by NB-UVB therapy, we here observed that NB-UVB therapy normalized the levels of endocan-1 and CXCL16 to the levels of the control subjects, and further reduced the levels of sVEGFR1. This altered response indicates that these mediators might be susceptible enough to treatment to properly identify and characterize the response.
Endocan-1 has previously been linked to endothelial dysfunction, a hallmark of atherosclerosis, and is being explored as a prognostic factor/biomarker in sepsis, cancer, and cardiovascular disease. Under normal physiological conditions, endocan-1 is vasoprotective, but levels of endocan-1 are increased in many inflammatory and hypervascular states, perhaps as a protective response. Low levels may therefore point to diminished vasoprotective effects [14] [15] [16] [17] . Furthermore, decreased endocan-1 levels are described in overweight and nonalcoholic fatty liver disease, conditions overexpressed in psoriasis [17] [18] [19] [20] .
The reduction in endocan-1 that we observed is also interesting in the context of leukocyte extravasation, where endocan-1 inhibits the extravasation process by preventing the binding of lymphocyte function-associated antigen (LFA) 1 to intracellular adhesion molecule (ICAM) 1 [21] . Interestingly, we have previously found elevated levels of soluble ICAM-1 in this psoriasis population [13] . It may be speculated that the reduced endocan-1 levels may be the result of a feedback loop stemming from the increased levels of ICAM-1, and that the low levels of endocan-1 may result in a lack of inhibition of leukocyte transmigratory responses. Such a mechanism has also been proposed in atopic dermatitis [22] .
Previous studies on endocan-1 in psoriasis have been contradictory. Balta et al. [23] identified elevated levels of endocan-1 in psoriasis, which also correlated positively to disease severity. However, this elevation was not replicated by Erek Toprak et al. [24] , who found no differences in endocan-1 levels between psoriasis patients and controls. This emphasizes that the role of endocan-1 in psoriasis is uncertain and not yet fully explored.
We also found notably lower levels of CXCL16 in our psoriasis patients than in the controls. CXCL16 is produced constitutively by keratinocytes and expressed by macrophages in atherosclerotic lesions. The relationship between circulating levels of soluble CXCL16 and atherosclerotic disorders remains controversial in clinical practice. Both decreased and increased CXCL16 levels have been reported in patients with atherosclerotic disorders [25] [26] [27] . CXCL16 is increased in lesional psoriatic skin, where it is most prominent in the lower epidermis [28] .
DOI: 10.1159/000491819
Compared to healthy and atopic dermatitic skin, monocytes, keratinocytes, and dendritic cells in psoriatic skin express a higher level of CXCL16 [29] . In contrast, previous studies on systemic levels of CXCL16 found no increase in the serum of psoriasis patients, and no correlation between CXCL16 levels and disease severity [30] .
Our measurements of soluble receptors in psoriasis revealed decreased levels of sVEGFR1. sVEGFR1 binds and sequesters vascular endothelial growth factor (VEGF), acting as an endogenous inhibitor of VEGF response [31] . This is particularly interesting in the context of psoriasis, where VEGF is overexpressed both in lesional skin and in serum [32] . sVEGFR1 is labelled a cardiovascular risk marker because of its association with endothelial dysfunction [33] . The reduced levels of sVEGFR1 in the plasma samples from psoriasis patients at baseline, along with its further reduction after NB-UVB treatment, may illustrate a dysfunctional VEGF pathway in psoriasis and an insufficient inhibition of VEGF, which, despite the reduction in sVEGFR1, is rendered less noticeable after UVB treatment due to the attenuating effect of UVB also on VEGF levels [34] . In serum from psoriasis patients with mild disease, Flisiak et al. [35] reported higher baseline levels of sVEGF1, which further increased upon topical treatment.
FABPs are key players in lipid homeostasis and comprise several isoforms. The heart and adipocyte isoforms FABP3 and 4 have been well studied in other systemic disorders but not fully investigated in psoriasis. FABP3 is highly expressed in cardiac and skeletal muscles, and its presence in blood is indicative of acute myocardial infarction [36] . FABP4, an adipokine and the most commonly occurring FABP isoform, is linked to obesity, diabetes, nonalcoholic fatty liver disease, and atherosclerosis [37, 38] .
We did not observe increased baseline levels of either FABP3 or FABP4 in our patients compared to the controls. However, NB-UVB treatment led to a significant reduction in both FABP3 and FABP4 levels, suggesting an influence of UVB on lipid metabolism through these isoforms. Our results are partially in agreement with a recently published paper by Baran et al. [39] , reporting no differences in baseline levels of FABP3 between patients and controls. In contrast to our results, they reported increased baseline FABP4 levels in their patients, which were not altered upon topical treatment.
In this study, we screened a large number of putative biomarkers for systemic inflammation in psoriasis. They were selected based on previous associations with the risk of cardiovascular disease. Numerous studies have been performed with the aim of establishing soluble biomarkers for systemic inflammation in psoriasis. However, most of the biomarkers that have been studied have not succeeded in meeting the criteria for a clinically useful biomarker. This work contributes by the evaluation of a larger number of candidate biomarkers in psoriasis. It is apparent that further studies are needed to elucidate the role of the investigated biomarkers in the pathogenesis of psoriasis and its comorbidities.
Key Message
Decreased systemic levels of the cardiovascular markers endocan-1 and CXCL16 are restored following UVB therapy.
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